Entecavir‐resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization
- 25 March 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 40 (7), 1564-1577
- https://doi.org/10.1111/liv.14446
Abstract
Background & Aim Since polymerase and surface genes overlap in hepatitis B virus (HBV), an antiviral‐induced mutation in the polymerase gene may alter the surface antigenicity in patients with chronic hepatitis B (CHB), but this possibility has not been clearly confirmed. This study aimed to determine the drug susceptibility and surface antigenicity of the patient‐derived mutants. Patients and Methods Full‐length HBV genomes isolated from four entecavir‐resistant CHB patients were cloned and sequenced. Around 10 clones of full‐length HBV obtained from each patient were analyzed and registered in the NCBI GenBank. Representative clones were further characterized by in vitro drug susceptibility and surface antigenicity assays. Results The rtL180M+rtM204V mutations were common among all the clones analyzed. Additionally, the ETV‐resistance mutations rtT184A/L, rtS202G, and rtM250V were found among three patients. Most of the ETV‐resistant mutants had amino acid alterations within the known epitopes recognized by T‐ and B‐cells in the HBV surface and core antigens. The in vitro drug susceptibility assay showed that all tested clones were resistant to ETV treatment. However, they were all susceptible to ADV and TDF. More importantly, the rtI169T mutation in the RT domain, led to the sF161L mutation in the overlapping S gene, which decreased in surface antigenicity. Conclusions The ETV‐resistance mutations can affect the antigenicity of the HBsAg proteins due to changes in the overlapping sequence of this surface antigen. Thus, the apparent decline or disappearance of HBsAg needs to be interpreted cautiously in patients with previous or current antiviral‐resistance mutations.Keywords
Funding Information
- Korea Health Industry Development Institute (HI17C0874)
- National Research Foundation of Korea (NRF‐2017R1A2B3006335, NRF‐2018M3A9H302084413)
This publication has 48 references indexed in Scilit:
- Discovery and Development of Anti-HBV Agents and Their ResistanceMolecules, 2010
- Short Communication: Transmission of Hepatitis B Viruses with Lamivudine Resistance Mutations in Newly Diagnosed HIV IndividualsAIDS Research and Human Retroviruses, 2009
- Chronic hepatitis B: Update 2009Hepatology, 2009
- Antiviral resistance and hepatitis B therapyHepatology, 2009
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyHepatology, 2009
- Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee modelHepatology, 2008
- Hepatitis B virus genetic diversity and its impact on diagnostic assaysJournal of Viral Hepatitis, 2007
- Successful treatment of an entecavir‐resistant hepatitis B virus variantJournal of Medical Virology, 2007
- Evolution of multi-drug resistant hepatitis B virus during sequential therapyHepatology, 2006
- Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantationHepatology, 1998